VSTMHIGH SIGNALOPPORTUNITY10-K

VSTM has transitioned from pre-revenue development stage to commercial operations with their approved AVMAPKI FAKZYNJA CO-PACK product, evidenced by dramatic revenue growth and substantially improved financial position.

The company has achieved a major milestone by bringing their first commercial product to market, generating $30.9M in revenue compared to minimal revenue previously. The transformation from negative stockholders' equity to positive $57.2M indicates successful financing and/or commercial traction that has fundamentally strengthened the balance sheet, though increased operating losses suggest they're investing heavily in commercialization.

Comparing 2026-03-04 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

VSTM's financials reflect a company in commercial transition, with revenue surging 209% to $30.9M and cash position more than doubling to $205M, providing substantial runway for operations. However, net losses increased 60% to $209.5M as SG&A expenses nearly doubled to $81.1M, indicating heavy investment in commercial infrastructure and market penetration. The dramatic improvement in stockholders' equity from negative $28.9M to positive $57.2M signals successful capital raising and/or milestone payments that have fundamentally strengthened the company's financial foundation.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+298%
-$28.9M$57.2M

Equity base grew 298% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+209.1%
$10.0M$30.9M

Strong top-line growth of 209.1% — accelerating demand or successful expansion into new markets.

Total Assets
Balance Sheet
+142.7%
$101.5M$246.4M

Asset base grew 142.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+135.3%
$95.0M$223.4M

Current assets grew 135.3% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+133.3%
$31.0M$72.3M

Current liabilities surged 133.3% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
+130.8%
$88.8M$205.0M

Cash position surged 130.8% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
+86%
$43.6M$81.1M

SG&A up 86% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Capital Expenditure
Cash Flow
-85.7%
$196K$28K

Capex reduced 85.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-75.1%
$4.6M$1.1M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
-60.3%
-$130.6M-$209.5M

Net income declined 60.3% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-20
ADDED
( Pfizer ) may fail to fully perform under the license agreement covering certain Pfizer FAK inhibitors, including defactinib; that we or Chugai Pharmaceutical, Co.
Other risks and uncertainties include those identified under the heading Risk Factors contained in this Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission ( SEC ) on March 4, 2026, and in any subsequent filings with the SEC.
Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading Item 1A.
You should carefully consider the risks that are summarized below and discussed in greater detail in the above mentioned section before making an investment decision.
If any of the following risks and uncertainties actually occur, our business, financial condition, and results of operations could be negatively impacted, and you could lose all or part of your investment.
+7 more — sign up free →
REMOVED
These forward-looking statements generally can be identified by the use of words such as anticipate, expect, plan, could, may, believe, estimate, forecast, goal, potentially, project, and other words of similar meaning.
All statements, other than statements related to present facts or current conditions or historical facts, contained in this Annual Report on Form 10-K are forward-looking statements, including statements regarding our strategy, future operations, future financial position, including our ability to continue as a going concern through one year from the date of the audited financial statements for the year ended December 31, 2024, future revenues, projected costs, prospects, plans and objectives of management.
Such statements relate to, among other things, the development and activity of our programs and product candidates, avutometinib (rapidly accelerated fibrosarcoma ( RAF )/ mitogen-activated protein kinase kinase ( MEK ) program) and defactinib (focal adhesion kinase ( FAK ) program), the timing and outcome of the U.S.
Other risks and uncertainties include those identified under the heading Risk Factors in this Annual Report on Form 10-K, and in any subsequent filings with the Securities and Exchange Commission ( SEC ).
Business OVERVIEW We are a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma ( RAS )/ mitogen activated pathway kinase ( MAPK ) pathway-driven cancers.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →